The study author, director of MedStar Georgetown Headache Center, and associate professor of neurology at MedStar Georgetown University Hospital discussed the findings of a pooled analysis of the ACHIEVE I and II studies of ubrogepant.
The director of the Headache Center of Southern California discussed the findings of the study, as well as what these data might suggest about how onabotulinumtoxinA fits into the shifting landscape of chronic migraine care.
The neurologist at the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic discussed how the agent might fit into the treatment landscape if its sBLA is approved by the FDA later this year.
The neurologist at Banner-University Medicine Neuroscience Institute offered his perspective on data from an open-label safety assessment of cannabidiol (Epidiolex) in the treatment of tuberous sclerosis complex.
The director of MedStar Georgetown Headache Center and associate professor of neurology at MedStar Georgetown University Hospital discussed the findings of an analysis from the ACHIEVE studies of ubrogepant.